Spectral awaits broader cardiac patent:
This article was originally published in Clinica
Executive Summary
The US Patent Office says it will issue a new, broader cardiac panel testing patent to Spectral Diagnostics. Spectral's original 1994 patent covered panel tests using myoglobin, myosin light-chains and either CK-MB, troponin-I or troponin-T, in chest pain patients. The new patent will extend the range of analyte combinations and be independent of test format. New analytes include glycogen phosphorylase, fatty acid binding proteins and carbonic anhydrase, among others.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.